SETD2 and cancer: An evolutionary study by the TRAcking Cancer Evolution through Therapy consortium identified frequent driver mutations in SETD2, BAP1, KDM5C, MTOR, PIK3CA, PTEN, p53, and KDM6A, often occurring at the subclone level [35].